135:. Many of its grants are structured as investments, providing a return that is reinvested in new drug research. After initial ADDF funding, grantees have received commitments of over $ 2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance drug research.
187:
Though more than 300 potential treatments for
Alzheimer's have been shown to have some positive effect when tested in animals, most have not been tested in humans because of the high costs of even modest clinical trials. The ADDF's Program to Accelerate Clinical Trials (PACT) works to accelerate this
199:
Through PACT, the ADDF is funding a number of "repurposing" clinical trials, whereby drugs developed for other indications (e.g., diabetes) are tested for their effectiveness in
Alzheimer's disease. Because these drugs have already passed significant safety tests, the risk of failure is reduced and,
216:
The ADDF hosts, sponsors and attends a number of scientific conferences, including the
International Conference on Alzheimer's Drug Discovery and the Drug Discovery for Neurodegeneration Conference. The ADDF also organizes advisory panels focused on key issues surrounding drug discovery and
613:
Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM (2014).
512:
Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM (2011).
948:
229:(CROs) and experimental tools. It provides Alzheimer's scientists with educational materials on the drug discovery process and guidance and expertise on the process of selecting and managing CRO relationships.
241:
Expert ratings of scientific evidence for and against suggested cognitive vitality strategies including: health management and drugs; nutrition and supplements; and environmental and physical considerations
938:
260:
The Great Ladies
Fashion Show and Luncheon, an annual spring runway show and lunch recognizing female advocates in Alzheimer's. Previous events have included designs and special appearances by
208:
The ADDF partners with family foundations, government, non-profit organization, the pharmaceutical industry and corporate organizations to leverage collective funding power.
278:
The Fall
Symposium and Luncheon, a luncheon and learning event featuring a keynote speech or panel highlighting progress in cognitive decline research and drug development.
108:
that might otherwise go unfunded. By supporting research projects around the world, it seeks to increase the chances of finding treatments for
Alzheimer's disease, related
167:
program funds research focused on translating existing knowledge about the underlying causes of
Alzheimer's disease into drug discovery. Areas of research include:
100:
cosmetics family and led by Howard Fillit, a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative
902:
864:"20th International Conference on Alzheimer's Drug Discovery | Alzheimer's Drug Discovery Foundation | Alzheimer's Drug Discovery Foundation"
566:"Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease"
394:
123:
The ADDF also publishes peer-reviewed scientific articles with the goal of accelerating and improving
Alzheimer's disease drug discovery research.
490:
179:, therapies, mitochondria function and inflammation. In 2013, 69 percent of the ADDF's drug portfolio was focused on preclinical drug discovery.
738:
256:
Every year, the ADDF hosts a series of events to raise awareness and funds to support
Alzheimer's research and drug development. They include:
365:
237:
The ADDF's microsite, Cognitive
Vitality, provide evidence-based answers to pressing questions about healthy brain aging. Resources include:
269:
36:
Alzheimer's Disease Preclinical Drug Research, Program to Accelerate Clinical Trials, Cognitive Vitality and Prevention, ADDF Access
226:
863:
200:
if pharmaceuticals are found to be effective in Alzheimer's patients, they can be brought more rapidly to market.
97:
884:
445:
275:
The Connoisseur's Dinner, an evening of art and wine celebrating scientific progress in Alzheimer's research.
943:
775:"Events & Conferences - Alzheimer's Drug Discovery Foundation - Alzheimer's Drug Discovery Foundation"
756:
101:
85:
261:
370:
903:"4th Annual Fall Luncheon & Symposium: Hope on the Horizon - Alzheimer's Drug Discovery Foundation"
132:
682:"Research Portfolio - Alzheimer's Drug Discovery Foundation - Alzheimer's Drug Discovery Foundation"
515:"Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies"
595:
143:
Through its programs, the ADDF has invested close to $ 65 million to fund nearly 450 Alzheimer's
757:"Drug Repurposing - October 1, 2012 Issue - Vol. 90 Issue 40 - Chemical & Engineering News"
645:
587:
546:
152:
89:
681:
192:" data. The PACT program also supports targeted approaches to prevention as well as clinical
635:
627:
577:
536:
526:
420:
189:
112:
and cognitive aging. The ADDF has invested nearly $ 65 million to fund some 450 Alzheimer's
93:
225:
The ADDF's ACCESS program connects scientists with networks of collaborators, consultants,
168:
105:
827:
792:
366:"Alzheimer's Drug Discovery Foundation features Paula Zahn, raises more than $ 2 million"
640:
615:
541:
514:
319:"Staff - Alzheimer's Drug Discovery Foundation - Alzheimer's Drug Discovery Foundation"
144:
113:
806:
188:
process, to date giving 32 clinical stage programs the chance to generate safety and "
932:
699:
148:
117:
599:
296:
720:
845:
774:
846:"Cognitive Vitality - Cognitive Vitality - Alzheimer's Drug Discovery Foundation"
446:"Patient Organizations - National Institute of Neurological Disorders and Stroke"
151:
companies in 18 countries. From 2000 to 2004, the ADDF provided seed funding for
318:
164:
631:
582:
565:
104:
drug research worldwide. The ADDF funds early-stage research and early-phase
885:"Eighth Annual Connoisseur's Dinner - Alzheimer's Drug Discovery Foundation"
193:
649:
591:
550:
663:
339:
265:
109:
721:"Alzheimer's Disease Research - Alzheimer's Drug Discovery Foundation"
531:
464:
155:, the first FDA-approved diagnostic test for Alzheimer's disease.
793:"ADDF's International Conference on Alzheimer's Drug Discovery -"
616:"Developing novel blood-based biomarkers for Alzheimer's disease"
465:"Making an Argument for a Narrower Focus in Charitable Donations"
176:
807:"ADDF's Drug Discovery for Neurodegeneration Conference |"
60:
Dr. Howard Fillit, Executive Director and Chief Science Officer
923:
172:
68:
564:
Dacks, P.A.; Shineman, D.W.; Fillit, H.M. (March 17, 2013).
949:
Medical and health organizations based in New York (state)
244:
Practical information on safety, efficacy and drug dosage
739:"What new Alzheimer's treatments are on the horizon?"
491:"Why isn't more being done for Alzheimer's research?"
147:
programs and clinical trials in academic centers and
116:
programs and clinical trials in academic centers and
939:
Medical and health foundations in the United States
715:
713:
395:"Lauder, Crowns bring Alzheimer's fight to Chicago"
64:
54:
40:
32:
24:
664:"About Us - Alzheimer's Drug Discovery Foundation"
247:Digestible translations of scientific findings
8:
19:
334:
332:
570:The Journal of Nutrition, Health and Aging
18:
639:
581:
540:
530:
20:The Alzheimer's Drug Discovery Foundation
288:
425:Alzheimer's Drug Discovery Foundation
393:Bertagnoli, Lisa (November 5, 2012).
344:Alzheimer's Drug Discovery Foundation
183:Program to Accelerate Clinical Trials
78:Alzheimer's Drug Discovery Foundation
7:
489:Shriver, Maria (September 2, 2013).
463:Sullivan, Paul (December 24, 2012).
28:Leonard A. Lauder, Ronald S. Lauder
364:Donnelly, Shannon (May 22, 2013).
14:
374:. Palm Beach, FL: Cox Media Group
828:"ADDF Access - Science Exchange"
227:contract research organizations
88:founded in 1998 by co-chairmen
1:
217:development for Alzheimer's.
401:. Crain Communications, Inc
120:companies in 18 countries.
965:
704:amyvid.myregistrationp.com
632:10.1016/j.jalz.2013.10.007
620:Alzheimer's & Dementia
159:Preclinical Drug Discovery
583:10.1007/s12603-012-0431-3
421:"ADDF Research Portfolio"
131:The ADDF is a biomedical
297:"Topics: Leonard Lauder"
832:www.scienceexchange.com
809:. Worldeventsforum.com
212:Scientific Conferences
98:Estée Lauder Companies
86:nonprofit organization
16:Nonprofit organization
371:Palm Beach Daily News
299:. Wall Street Journal
907:www.alzdiscovery.org
889:www.alzdiscovery.org
850:www.alzdiscovery.org
779:www.alzdiscovery.org
725:www.alzdiscovery.org
686:www.alzdiscovery.org
668:www.alzdiscovery.org
323:www.alzdiscovery.org
204:Partnership Programs
175:-related therapies,
133:venture philanthropy
519:Alzheimers Res Ther
102:Alzheimer's disease
21:
866:. Alzdiscovery.org
233:Cognitive Vitality
450:www.ninds.nih.gov
90:Leonard A. Lauder
74:
73:
956:
924:Official Website
911:
910:
899:
893:
892:
881:
875:
874:
872:
871:
860:
854:
853:
842:
836:
835:
824:
818:
817:
815:
814:
803:
797:
796:
789:
783:
782:
771:
765:
764:
753:
747:
746:
735:
729:
728:
717:
708:
707:
696:
690:
689:
678:
672:
671:
660:
654:
653:
643:
610:
604:
603:
585:
561:
555:
554:
544:
534:
509:
503:
502:
500:
498:
486:
480:
479:
477:
475:
460:
454:
453:
442:
436:
435:
433:
431:
417:
411:
410:
408:
406:
399:Chicago Business
390:
384:
383:
381:
379:
361:
355:
354:
352:
350:
336:
327:
326:
315:
309:
308:
306:
304:
293:
270:Carolina Herrera
190:proof-of-concept
94:Ronald S. Lauder
69:Official website
22:
964:
963:
959:
958:
957:
955:
954:
953:
929:
928:
920:
915:
914:
901:
900:
896:
883:
882:
878:
869:
867:
862:
861:
857:
844:
843:
839:
826:
825:
821:
812:
810:
805:
804:
800:
791:
790:
786:
773:
772:
768:
755:
754:
750:
737:
736:
732:
719:
718:
711:
698:
697:
693:
680:
679:
675:
662:
661:
657:
612:
611:
607:
563:
562:
558:
532:10.1186/alzrt90
511:
510:
506:
496:
494:
488:
487:
483:
473:
471:
462:
461:
457:
444:
443:
439:
429:
427:
419:
418:
414:
404:
402:
392:
391:
387:
377:
375:
363:
362:
358:
348:
346:
338:
337:
330:
317:
316:
312:
302:
300:
295:
294:
290:
285:
254:
235:
223:
214:
206:
185:
169:neuroprotection
161:
141:
129:
106:clinical trials
57:
50:
17:
12:
11:
5:
962:
960:
952:
951:
946:
944:Social finance
941:
931:
930:
927:
926:
919:
918:External links
916:
913:
912:
894:
876:
855:
837:
819:
798:
784:
766:
748:
730:
709:
691:
673:
655:
605:
556:
504:
481:
469:New York Times
455:
437:
412:
385:
356:
328:
310:
287:
286:
284:
281:
280:
279:
276:
273:
253:
250:
249:
248:
245:
242:
234:
231:
222:
219:
213:
210:
205:
202:
184:
181:
160:
157:
145:drug discovery
140:
137:
128:
125:
114:drug discovery
72:
71:
66:
62:
61:
58:
55:
52:
51:
49:
48:
44:
42:
38:
37:
34:
30:
29:
26:
15:
13:
10:
9:
6:
4:
3:
2:
961:
950:
947:
945:
942:
940:
937:
936:
934:
925:
922:
921:
917:
908:
904:
898:
895:
890:
886:
880:
877:
865:
859:
856:
851:
847:
841:
838:
833:
829:
823:
820:
808:
802:
799:
794:
788:
785:
780:
776:
770:
767:
762:
758:
752:
749:
744:
740:
734:
731:
726:
722:
716:
714:
710:
705:
701:
695:
692:
687:
683:
677:
674:
669:
665:
659:
656:
651:
647:
642:
637:
633:
629:
626:(1): 109–14.
625:
621:
617:
609:
606:
601:
597:
593:
589:
584:
579:
576:(3): 240–51.
575:
571:
567:
560:
557:
552:
548:
543:
538:
533:
528:
524:
520:
516:
508:
505:
492:
485:
482:
470:
466:
459:
456:
451:
447:
441:
438:
426:
422:
416:
413:
400:
396:
389:
386:
373:
372:
367:
360:
357:
345:
341:
335:
333:
329:
324:
320:
314:
311:
298:
292:
289:
282:
277:
274:
271:
267:
263:
259:
258:
257:
251:
246:
243:
240:
239:
238:
232:
230:
228:
220:
218:
211:
209:
203:
201:
197:
196:development.
195:
191:
182:
180:
178:
174:
170:
166:
158:
156:
154:
150:
149:biotechnology
146:
139:ADDF programs
138:
136:
134:
127:Funding model
126:
124:
121:
119:
118:biotechnology
115:
111:
107:
103:
99:
95:
91:
87:
83:
79:
70:
67:
63:
59:
53:
46:
45:
43:
39:
35:
31:
27:
23:
906:
897:
888:
879:
868:. Retrieved
858:
849:
840:
831:
822:
811:. Retrieved
801:
787:
778:
769:
760:
751:
742:
733:
724:
703:
694:
685:
676:
667:
658:
623:
619:
608:
573:
569:
559:
522:
518:
507:
495:. Retrieved
484:
472:. Retrieved
468:
458:
449:
440:
428:. Retrieved
424:
415:
403:. Retrieved
398:
388:
376:. Retrieved
369:
359:
347:. Retrieved
343:
340:"About ADDF"
322:
313:
301:. Retrieved
291:
255:
236:
224:
215:
207:
198:
186:
162:
142:
130:
122:
81:
77:
75:
47:New York, NY
761:cen.acs.org
743:Mayo Clinic
221:ADDF ACCESS
165:preclinical
163:The ADDF's
933:Categories
870:2019-06-01
813:2019-06-01
283:References
56:Key people
525:(5): 28.
194:biomarker
110:dementias
650:24365657
600:23548988
592:23459977
551:21943025
497:April 2,
474:April 2,
430:April 2,
405:April 2,
378:April 2,
349:April 2,
303:April 2,
266:Jason Wu
41:Location
641:4769619
542:3218805
493:. MSNBC
96:of the
84:) is a
65:Website
25:Founder
700:"HOME"
648:
638:
598:
590:
549:
539:
252:Events
153:Amyvid
596:S2CID
262:Erdem
33:Focus
646:PMID
588:PMID
547:PMID
499:2014
476:2014
432:2014
407:2014
380:2014
351:2014
305:2014
268:and
177:ApoE
92:and
82:ADDF
76:The
636:PMC
628:doi
578:doi
537:PMC
527:doi
173:tau
935::
905:.
887:.
848:.
830:.
777:.
759:.
741:.
723:.
712:^
702:.
684:.
666:.
644:.
634:.
624:10
622:.
618:.
594:.
586:.
574:17
572:.
568:.
545:.
535:.
521:.
517:.
467:.
448:.
423:.
397:.
368:.
342:.
331:^
321:.
264:,
171:,
909:.
891:.
873:.
852:.
834:.
816:.
795:.
781:.
763:.
745:.
727:.
706:.
688:.
670:.
652:.
630::
602:.
580::
553:.
529::
523:3
501:.
478:.
452:.
434:.
409:.
382:.
353:.
325:.
307:.
272:.
80:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.